Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Other Working Capital Changes (2017 - 2024)

Solid Biosciences' Other Working Capital Changes history spans 8 years, with the latest figure at -$398000.0 for Q3 2024.

  • For Q3 2024, Other Working Capital Changes fell 29.64% year-over-year to -$398000.0; the TTM value through Sep 2024 reached $682000.0, up 111.55%, while the annual FY2023 figure was -$1.7 million, 4849.39% down from the prior year.
  • Other Working Capital Changes for Q3 2024 was -$398000.0 at Solid Biosciences, down from $41659.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $4.8 million in Q3 2022 and bottomed at -$9.0 million in Q3 2021.
  • The 5-year median for Other Working Capital Changes is -$611000.0 (2023), against an average of -$1.1 million.
  • The largest annual shift saw Other Working Capital Changes crashed 724.63% in 2021 before it soared 258.45% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at $1.4 million in 2020, then tumbled by 314.44% to -$3.0 million in 2021, then plummeted by 56.95% to -$4.8 million in 2022, then skyrocketed by 87.21% to -$611000.0 in 2023, then surged by 34.86% to -$398000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Other Working Capital Changes are -$398000.0 (Q3 2024), $41659.0 (Q2 2024), and $2.0 million (Q1 2024).